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doi:10.1016/j.ejvs.2008.03.014Abstract Objective: To assess changes in great saphenous vein (GSV) diameter and the signif-
icance of re-canalisation following endovenous laser ablation (EVLA).
Design: Prospective cohort study.
Methods: Two groups were studied. Group A: 73 consecutive patients (84 GSVs) underwent EVLA
followed by duplex ultrasound at 6, 12 and 52 weeks. Vein diameter and patency were recorded.
Group B: From a prospectively maintained database 27 patients with a GSV that was found to
have recanalised 6-12 weeks post-EVLA were identified and rescanned at 52 weeks. Pre- and
post-treatment Aberdeen varicose vein severity scores (AVVSS) were measured.
Results: Group A: 81/84 (96%) GSVs were ablated and 3/84 (4%) had re-canalised (flash reflux
<1 s). GSV diameter diminished with time: pre-EVLA: mean diameter 7.7 S.D .2.0 mm; 6 weeks:
5.1 S.D. 1.3 mm; 12 weeks: 3.2 S.D. 1.2; 52 weeks: 85% non-visible (p< 0.001). Group B: 3/27
(11%) with reflux >1 s underwent repeat EVLA. 16/27 (59%) remained competent at 52 weeks
and 8/27 (30%) showed trickle reflux. Vein diameter decreased in both subgroups (mean dia-
meter 7.3 S.D. 2.5 mm to 3.1 S.D. 0.8 mm (pZ 0.006) and 7.2 S.D. 2.3 mm to 3.0 S.D. 0.7 mm
(pZ 0.009) respectively) as did the AVVSS (p< 0.001).
Conclusions: Successful EVLA causes GSV shrinkage with transition from a non-compressible
‘‘thrombosed’’ vein to a non-visible vein by 1 year. A re-canalised GSVusually remains small with
no/minimal reflux and persisting clinical benefit.
ª 2008 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.cumar, General Infirmary at
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ty for Vascular Surgery. PublisheIntroduction
The majority (70%)1 of varicose veins are the result of
sapheno-femoral junction (SFJ) and great saphenous vein
(GSV) incompetence, and are increasingly treated byd by Elsevier Ltd. All rights reserved.
Table 1 Patients demographic details and the CEAP
classification before EVLA
Characteristics Group A (%) Group B (%)
Male 31 (42%) 10 (37%)
Female 42 (58%) 17 (63%)
Age, median (range) 50 (26e76)
years
51 (33e72)
years
Number of Limbs studied 84 27
CEAP-C2 46 (55%) 18 (67%)
C3 11 (13%) 4 (15%)
C4 19 (23%) 3 (11%)
C5 6 (7%) 2 (7%)
C6 2 (2%) 0
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ablation (EVLA). Although EVLA is effective (88e100%) in
ablating the GSV,2e4 critics of the technique suggest that
it induces thrombotic GSV occlusion which has a significant
risk of re-canalisation rather than inducing obliteration of
the vein. Further it is suggested that re-canalisation results
in loss of the therapeutic benefit. This observational cohort
study has investigated these two issues.
Methods
Patients
Seventy-three consecutive patients (84 limbs) underwent
above-knee GSV EVLA for primary varicose veins in order to
treat varicose veins arising from SFJ/GSV reflux between
March 2005 and November 2005 and completed 1 year
follow up (Group A). A further group of 27 patients (Group
B) with re-canalisation of a previously treated GSV were
identified from a prospectively maintained database of
patients undergoing EVLA during the previous 3 years.
Group A patients were used to exemplify the current
frequency of re-canalisation following EVLA in our centre
and acted as a control group for comparison with group B,
all of whom had a re-canalised GSV.
Data collection
Pre-treatment disease severity was assessed using the CEAP
classification, Aberdeen varicose vein severity score
(AVVSS) and venous clinical severity score (VCSS). The
maximum GSV diameter was measured whilst standing. All
patients underwent GSV EVLA using an 810 nm diode pulsed
laser (EVLT, Diomed Inc, Andover, MA, USA) at 12 W power
with intermittent laser fibre withdrawal, using the method
previously described.5 The vein was ablated from the groin
(SFJ) to the level of the knee. Following EVLA a duplex
ultrasound scan (TITAN, Sonosite Inc, Bothell, USA, 5e
10 MHz linear probe) was performed at 6, 12 and 52 weeks
to assess echogenicity, compressibility, diameter and flow
status of the treated segment of GSV. Absence of flow in
a non-compressible vein or a non-visible GSV represented
successful ablation. Re-canalisation was considered to
have occurred when either antegrade or retrograde blood
flow was present in a compressible vein (segmental or full
length). Compressibility and flow in the femoral and popli-
teal veins was assessed at each visit to identify a deep vein
thrombosis. The calf veins were not scanned unless the
patient reported possible symptoms of a DVT. Foam sclero-
therapy was used to treat any residual varicosities in the
study limbs at 6 week follow up. AVVSS and VCSS were
reassessed at 1 year and clinical recurrence of varicose
veins documented. All data were recorded prospectively
in both groups of patients. For the purpose of disease sever-
ity comparison, patients with a re-canalised GSV in group A
were included in group B.
Statistical analysis
Symptom improvement (AVVSS, VCSS) was assessed using
a Wilcoxon paired test within each group. Comparisonbetween groups was performed using a Mann-Whitney U
test and a student-t test employed to assess the metric
data (vein diameter). The descriptors used for non-
normally distributed are the median (inter-quartile range)
and for data with a Gaussian distribution the mean and
standard deviation have been used. All analysis were
performed using statistical package SPSS for Windows
(SPSS, Chicago, Illinois, USA).
Results
Demographic data and the CEAP grading for the study limbs
are shown in Table 1. GSV length and pre-treatment diame-
ters were similar in both groups (Table 2). In particular there
was no difference in the maximum pre-treatment diameters
in patients with an occluded or re-canalised vein.
Group A
The GSV was occluded in all 84 limbs (no flow, non-
compressible vein) at 6 weeks but 3/84 (3.5%) veins showed
evidence of re-canalisation without significant reflux at 12
weeks. These veins remained patent with only flash reflux
(<1 s) at one year with no evidence of recurrent varicosi-
ties. There were no new instances of re-canalisation after
3 months. None of the post-EVLA scans showed any sign
of deep vein thrombosis. In all patients the GSV diameter
became progressively smaller during follow-up (Table 3),
with 70/82 (85%) being non-visible at 12 months. In 9 limbs
a small (z2 mm diameter) iso-echoic or hyper-echoic nidus
remained visible within the saphenous space without
a demonstrable lumen or flow. These veins were considered
to be occluded. The ultrasound findings are summarised in
Table 3. Limbs in group A received a median of 66
(55e74) J/cm laser energy.
Group B
Of the 27 patients in group B, 3 had significant GSV reflux
(>1 s) and persisting varicosities on their 6 weeks post-EVLA
scan suggesting primary treatment failure. All were success-
fully re-treated with EVLA. Although 1 patient was taking
warfarin and another had removed the compression bandage
early, all had received low dose laser energy (44, 48, 38 J/cm)
Table 2 Comparison of pre-treatment diameter of the
vein and the length of vein treated between groups
Group A Group B p
Diameter of
the vein (mm)
7.7 S.D. 2.0 7.9 S.D. 1.6 0.23
Length of vein
treated (cm)
33 S.D. 8 31 S.D. 6 0.34
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a whole was 42 (37e55) J/cm. Primary failure of EVLA is
suggested by the persisting large diameter (5.2, 6.4,
7.3 mm) of the GSVs compared to that of the other patients
in group B who did not require re-treatment (3.0 S.D.
0.5 mm) including 6 patients with patent, small diameter
veins and no or flash reflux at 6 weeks. The remaining 18 pa-
tients had evidence of re-canalisation at 12 weeks following
a satisfactory 6 week scan. During subsequent follow up
these GSVs remained unchanged in size (2.9 S.D. 0.8 at 12
weeks v 3.0 S.D. 0.7 at 1-year; pZ 0.33) with no clinical
evidence of recurrent varicosities. Finally, of the 24 patients
in group Bwho did not undergo repeat EVLA, DUS at 52weeks
showed no reflux in 16 (group BNR) whilst 8 (group BTR) had
evidence of trickle reflux (reflux >1 s but only detectable
on low-gain settings). The AVVSS improved from a median
of 13.4 (8.2e19.4) to 2.5 (0.7e3.6), p< 0.001 (Wilcoxon)
in group BNR and from a median of 14.8 (6.3e17.5) to 4.2
(2.2e8.1), p< 0.001 in group BTR. In both groups the GSV
was significantly smaller at 1 year than before treatment
(BNR: 7.3 S.D. 2.5 mm v 3.1S.D.0.8 mm [pZ 0.006, t-test];
BTR: 7.2 S.D. 2.3 mm v 3.0 S.D. 0.7 mm [pZ 0.009, t-test]).
Successful GSV ablation vs re-canalisation
At 1 year, the AVVSS improved from 15.1 (7.3e21.2) to 2.4
(1.1e4.2), p< 0.001 (Wilcoxon) and the VCSS from 4 (2e6) to
0 (0e2), p< 0.05 in patients who had successful GSV abla-
tion. Similar improvements were recorded in patients with
GSV re-canalisation, excluding the 3 primary treatment
failures: [AVVSS: 14.2 (7.4e18.1) v 3.3 (2.1e5.5), p< 0.001
(Wilcoxon) and VCSS: 4 (2e5) v 0 (0e2), p< 0.05]. There
was no difference in the percentage improvement in the
AVVSS score between the groups (group A: 82.4% (60.1e
98.2) v group B: 78.2% (55.3e92.3), pZ 0.24).Table 3 Comparison of the ultrasound findings of the treated s
Scan findings Pre
(NZ 84)
6-week
(nZ 84)
Diameter 7.7 S.D. 2.0 5.1 S.D. 1.3
*P< 0.01 (t-te
Hypo-echoic GSV 84 (100%) 62 (74%)
Iso-echoic GSV 0 19 (23%)
Hyper-echoic GSV 0 3 (3%)
GSV Not seen 0 0
GSV Re-canalisation N/A 0
* p-value for (pre versus 6 weeks).
** p-value for (6 versus 12 weeks).Discussion
Laser energy causes thermal injury to the endothelial and
sub-endothelial layers of the treated vein leading to fibro-
thrombosis.6,7 Scarcity of fibrosis during the initial post-treat-
ment period results in the typical hypo-echoic appearance on
ultrasound, similar to that of an acute thrombosis. With in-
creasing fibrous tissue formation over time, the ablated
GSV becomes iso-echoic or sometimes hyper-echoic before
becoming non-visible by 1 year (Fig. 1). Progressive devel-
opment of fibrosis and contraction explains the gradual
diminution in vein diameter following treatment. Further,
re-canalisation of the GSV did not occur >3 months after
EVLA, a finding confirmed by others.4
The results of this study suggest that when GSV re-canal-
isationoccurs6e12weeksafter treatment it is accompaniedby
vein shrinkage and continuing symptom relief, at least in the
short term. Thus the symptomatic improvement was main-
tained at 1 year although with longer follow-up it is possible
that both recurrent varicosities and symptoms might develop.
Interestingly conversion of a large diameter GSV to
a small, competent vein was the original aim of the
radiofrequency RESTORE system (VNUS Medical Technol-
ogies, Inc, Sunnyvale, California) which was subsequently
replaced by the CLOSURE device which aims to ablate the
GSV permanently. Unlike the present data for group B, both
symptoms and varicosities recurred following treatment
with RESTORE in most patients.8
In 3/27 group B patients the GSV remained at the
pre-treatment diameter with significant reflux at the first
follow up (6 weeks). It seems likely that these patients
represent primary treatment failures. Such a conclusion is
based on the low laser energy used in these patients, 2 of
whom also had other possible reasons for non occlusion
(warfarin, early removal of compression bandage). It is also
possible that these veins had been temporarily occluded
but underwent early thrombus dissolution allowing preser-
vation of the pre-treatment vein diameter. Regardless of
the cause of these early failures further treatment (repeat
EVLA or surgery) is likely to be required in this small
subgroup. Whilst other authors9 have suggested the use of
ultrasound guided foam sclerotherapy following GSV re-ca-
nalisation this technique was not used in patients with a pri-
mary treatment failure because of the relatively high risk of
further re-canalisation with this technique. Nevertheless it
may have a role in patients with segmental re-canalisation.egment of GSV before and after laser treatment in group A
12-week
(nZ 84)
One year
(nZ 82)
st)
3.2 S.D. 1.2
**P< 0.01 (t-test)
2.6 S.D. 0.7 (for the
visible veins, nZ 12)
12 (14%) 0
60 (71%) 5 (6%)
9 (11%) 4 (5%)
0 70 (85%)
3 (4%) 3 (4 %)
Figure 1 Ultrasound appearance of GSV after successful EVLA showing changes over time. A: GSV before EVLA (8.6 mm, hypo-
echoic, compressible); B: GSV 6 weeks after EVLA (7.8 mm, hypo-echoic, non-compressible: vein occluded); C: GSV 12 weeks after
EVLA (2.2 mm, iso-echoic, not compressible: vein ablated); D: GSV invisible 1 year after EVLA (arrow shows empty saphenous space).
214 N.S. Theivacumar et al.Although one of these patients was taking warfarin experi-
ence in other patients does not suggest that this, or antipla-
telet drugs need to be discontinued prior to EVLA provided
that >60 J/cm energy is delivered to the vein.5Figure 2 Ultrasound appearance of a re-canalised GSV at 3-mont
pre-EVLA size (5.9 mm).The mechanism for re-canalisation between 6e12 weeks
(the majority of ‘‘failures’’) is also open to debate. Whilst
thrombus dissolution is considered the most important
factor intra-luminal neovascularisation may also playhs. Note the re-canalised GSV is small (2.5 mm) compared to its
Fate of GSV after EVLA 215a role.10 If this occurs it is believed that a patent vaso
vasorum of the target vein continues to supply blood to
the fibrothrombus in the vein lumen bringing growth factors
that promote new vessel formation. Such neovascularisa-
tion may communicate with the patent vaso vasorum
forming an intra-luminal arterio-venous fistula. Regardless
of the mechanism re-canalised veins show evidence of
a significant diameter reduction (Fig. 2), with no or trickle
reflux and resolution of symptoms. These patients do not
require further treatment, at least within the first year.
Further follow up of these patients is required to determine
the medium / long term prognosis.
In conclusion, the GSV diameter diminishes over a period
of months following EVLA and most successfully ablated
veins (85%) are invisible by 1 year. Using current treatment
parameters (60 J/cm laser energy) GSV re-canalisation is
uncommon (4%) and occurs within 3 months of treatment.
In most cases re-canalisation does not lead to clinical recur-
rence or return of symptoms and does not require further
intervention. In patients with early re-canalisation (primary
treatment failure) repeat EVLA has proved successful.
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